Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental

Phase 3

Completed

• Conditions: Glomerulonephritis, Membranous; Glomerulosclerosis, Focal

• Registration Number: NCT00404833
• Lead Sponsor: Hospital Authority, Hong Kong

Brief Summary

This is a prospective randomized open-label pilot study to investigate the effect of mycophenolate mofetil treatment in patients with abnormal urine protein excretion due to membranous nephropathy (MN) or focal segmental glomerulosclerosis (FSGS). The change in urine protein excretion will be the primary outcome studied. The treatment regimen comprising prednisolone and mycophenolate mofetil will be compared with prednisolone and chlorambucil in MN, and compared with prednisolone in FSGS. The study duration will be 12 months for each patient.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Study First Submitted: 2006-11-27
• Study First Submitted QC: 2006-11-28
• Study First Posted: 2006-11-29
• Study Completion: 2006-12
• Status Verified: 2013-10
• Last Update Submitted: 2013-10-22
• Last Update Posted: 2013-10-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• abnormal urine protein excretion and biopsy-proven idiopathic membranous nephropathy or focal segmental glomerulosclerosis

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Proteinuria

Secondary Outcome Measures

Name	Time	Method
Adverse effects

Trial Locations

Locations (1)

Queen Mary Hospital; 🇨🇳 Hong Kong, China